Botulinum Neurotoxin-A therapy in patients with refractory overactive bladder

AbstractAim: The aim of this study was to evaluate the clinical efficacy and safety of intravesical botulinum neurotoxin-A injection in patients with refractory overactive bladder to conservative treatment and anti-muscarinic drugs.Material and Methods: The data of 62 patients, who received botulinum neurotoxin-A (BonTA) injection (100 U) for overactive bladder (OAB) between 2015 and 2019, were reviewed retrospectively. For 55 patients included into the study, the urinary frequency and urgency, the number of incontinence and nocturia episodes, the maximum flow rate (Qmax), the post-void residual volume (PVR), and the Urinary Incontinence Quality of Life (I-QoL) scores were evaluated before the treatment and at the third month after the treatment.Results: The comparison of the pre-treatment and posttreatment 3rd-month follow-up data revealed a statistically significant decrease in the urinary frequency and urgency, and the number of incontinence and nocturia episodes (p 0.05). The mean I-QoL score increased significantly in the posttreatment 3rd month compared to the pre-treatment scores (43.62 ± 11.2 and 75.2 ± 12.6, p = 0.001, respectively). After the treatment, hematuria developed in 3 female and 2 male patients and urinary tract infections developed in 4 females and 2 male patients.Conclusion: BonTA injection significantly improves the daily urinary frequency, incontinence, and quality of life scores in patients with OAB.

PDF

___

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Neurourol Urodyn 2002:21;167-78.
2. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:580.
3. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60:7.
4. Homma Y, Yamaguchi O, Hayashi K. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006;68:560.
5. Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008;72:803-7.
6. Astellas Pharma US, Inc. Myrbetriq (mirabegron) extended release tablets. US prescribing information. 2012. Available from: http://www. accessdata.fda. gov/drugsatfda_docs/label/ 2012/202611s000lbl.pdf [Accessed 12 December 2013]
7. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572.
8. Phé V, de Wachter S, Rouprêt M, et al. How to define a refractory idiopathic overactive bladder? Neurourol Urodyn 2015;34:2-11.
9. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) Guidelines on NeuroUrology. Eur Urol 2016;69:324-33.
10. Lucas MG, Bedretdinova D, Berghmans LC, et al. EAU 2015 guidelines on urinary incontinence. Available at: http://uroweb.org/ wp-content/uploads/EAUGuidelines-Urinary-Incontinence-2015.pdf.
11. Van Ermengem E. Ueber einen neuen anaeroben Bacillus and seine Beziehungen zum Botulisms.Ztsch Hyg Infekt 1897:26;1.
12. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006:175;2341-4.
13. Roosen A, Data SN, Chowdhury RA, et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 2009:55;1440-9.
14. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-20.
15. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-Adrenoceptor Agonist, in patients with Overactive Bladder: results from a randomized European-Australian Phase III trial. Eur Urol 2013;63:283-95.
16. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) efficacy results from a phase 2 study (symphony). J Urol 2013;189:803.
17. Dmochowski RR, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007; 99: 247-62.
18. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22.
19. Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebocontrolled trial of 240 women (the RELAX Study). Eur Urol 2012;62:507-14.
20. Leong RK, De Wachter SG, van Kerrebroeck PE. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010; 84:245-53.
21. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a doubleblind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416- 22.
22. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-a for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-6.
23. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo control¬led trial. J Urol 2013;189:2186-93.
24. Onem K, Bayrak O, Demirtas A, et al. Turkish Urology Academy, Incontinence/Neurourology Study Group. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population. Neurourol Urodyn 2017.
25. Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014;65:981-90.
26. Fowler C, Auerbach S, Ginsberg D, et al. Botulinum toxin A (BotoxR) demonstrates dose-dependent improvements in health-related quality-of-life measures in idiopathic overactive bladder. J Urol 2009;181:558.
27. López Ramos H, Torres Castellanos L, Ponce Esparza I, et al. Management of overactive bladder with onabotulinumtoxin A: systematic review and metaanalysis. Urology 2017;100:53-8.
28. Sun Y, Luo D, Tang C, et al. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol 2015;47:1779-88.
29. Anger JT, Weinberg A, Suttorp MJ, et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010;183:2258-64.